The promyelocytic leukemia zinc finger (PLZF) protein is involved in major biological processes including energy metabolism, although its role remains unknown. In this study, we demonstrated that hepatic PLZF expression was induced in fasted or diabetic mice. PLZF promoted gluconeogenic gene expression and hepatic glucose output, leading to hyperglycemia. In contrast, hepatic PLZF knockdown improved glucose homeostasis in db/db mice. Mechanistically, peroxisome proliferator-activated receptor ␥ coactivator 1␣ and the glucocorticoid receptor synergistically activated PLZF expression. We conclude that PLZF is a critical regulator of hepatic gluconeogenesis. PLZF manipulation may benefit the treatment of metabolic diseases associated with gluconeogenesis.
H
epatic gluconeogenesis plays an important role in the maintenance of blood glucose homeostasis in mammals. Under fasting conditions, pancreatic ␣-cells secrete glucagon, which stimulates glycogen breakdown (glycogenolysis) and generates glucose from the liver. Prolonged fasting or starvation induces de novo glucose synthesis in the liver, termed hepatic gluconeogenesis. In addition to glucagons, glucocorticoids are also important hormonal signals for initializing gluconeogenesis. The response to glucocorticoids is mediated by the glucocorticoid receptor (GR) that binds to glucocorticoid responsive elements in the promoters of gluconeogenic genes (1) . As is known, several key regulatory enzymes are required to correctly trigger the process of gluconeogenesis, including glucose 6-phosphatase (G6Pc), fructose 1,6-bisphosphatase, pyruvate carboxylase, and phosphoenolpyruvate carboxykinase (Pck1) (2, 3) . In contrast, under feeding conditions, insulin is secreted from pancreatic ␤-cells in response to the elevated levels of plasma glucose. In the liver, insulin inhibits glycogenolysis and gluconeogenesis while stimulating glycolysis and glycogenesis, thus reducing the plasma glucose levels in the body (4) . Hepatic gluconeogenesis is tightly controlled in healthy individuals; however, it is constitutively activated due to insulin resistance in certain pathophysiological conditions, such as type 2 diabetes, and leads to excess glucose secretion and aggravated hyperglycemia (5, 6) .
To date, numerous transcriptional regulators of hepatic gluconeogenesis have been identified. Among these, the transcriptional coactivator peroxisome proliferatoractivated receptor ␥ coactivator 1␣ (PGC-1␣) has gained a lot of attention because of its robust roles in the regulation of various metabolic pathways including hepatic gluconeogenesis (7) . In the liver, expression of PGC-1␣ is markedly induced upon fasting via a cAMP response element binding protein/cAMP response element binding protein-regulated transcription coactivator 2-dependent transcriptional mechanism (8) . Overexpression of PGC-1␣ in the mouse liver or primary hepatocytes increases the expression levels of gluconeogenic genes by enhancing the transactivating potential of various transcriptional factors such as GR, hepatocyte nuclear factor 4␣ (9) , and forkhead box class O1 (FoxO1) (10) . Conversely, either acute knock-down or knockout of PGC-1␣ in mice results in the lower blood glucose levels that are associated with the reduced expression of gluconeogenic genes (11) . These findings indicate that PGC-1␣ is a critical factor in the regulation of gluconeogenesis and glucose homeostasis.
The promyelocytic leukemia zinc finger (PLZF) protein, also known as Zbtb 16 or Zfp 145, was first identified in 1993 in a patient with acute promyelocytic leukemia, in whom a reciprocal chromosomal translocation t(11;17) (q23;q21) resulted in a fusion with the RARA gene encoding retinoic acid receptor ␣ (12) . PLZF has been shown to be involved in major developmental and biological processes, such as spermatogenesis (13) , hind limb formation (13) , hematopoiesis (14, 15) , and immune regulation (16) . Interestingly, recent studies have indicated that PLZF may potentially play a role in the pathogenesis of metabolic diseases. For example, a single nucleotide polymorphism leading to a threonine to serine substitution at amino acid position 208 (T208S) in the rat plzf gene not only results in the development of polydactyly-luxate syndrome but also affects total body weight, adiposity, the lipid profile, and the insulin sensitivity of skeletal muscle (17) . In addition, PLZF expression in visceral adipose tissue of obese diabetic women is significantly lower than that in healthy control women (18) . In contrast, PLZF overexpression in brown adipocytes leads to the induction of genes involved in fatty acid oxidation, glycolysis, and mitochondrial function (18) . Although these findings clearly demonstrate that PLZF is a robust metabolic regulator, they are generally descriptive and the detailed mechanism through which PLZF regulates energy metabolism remains unknown.
Based on the findings mentioned above, we aimed to explore whether PLZF regulates hepatic gluconeogenesis and whether this process requires PGC-1␣ participation. To answer this question, we used the gain-and loss-offunction strategy to manipulate the PLZF expression levels both in vivo and in vitro using adenoviral transduction and small interfering RNA (siRNA) delivery. Our studies revealed a positive role for PLZF in the regulation of gluconeogenesis and suggested that PLZF may be a therapeutic target for the treatment of various disorders associated with gluconeogenesis dysregulation.
Materials and Methods

Animal experiments
Eight-week-old male C57BL/6 mice and diabetic db/db mice on a C57BKS background were purchased from the Model Animal Research Center of Nanjing University. All animal procedures in this investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996) and the approved regulations set by the Laboratory Animal Care Committee at Nanjing Normal University (permit number 2090658, date issued April 20, 2008) . For the fasting time course experiment, mice were fed ad libitum or fasted during the dark period for 2, 5, and 16 hours. For the streptozotocin (STZ) (Sigma-Aldrich) diabetic mouse experiments, 6-to 8-week-old male mice were injected intraperitoneally for 2 days consecutively with either sodium citrate solution or STZ (125 mg/kg body mass). Animals were killed after 10 days, at which point the mean blood glucose in the STZ-treated group rose to Ͼ19.4 mM. To induce type 2 diabetes, 4-week-old mice were fed a high-fat diet (HFD) (fat content 60%; Research Diets) for 1 month and then challenged with STZ for 5 days at a dose of 25 mg/kg body mass through intraperitoneal injection.
Adenovirus and plasmid information
Adenoviruses (ad-green fluorescent protein [GFP], ad-PGC-1␣, ad-scrambled (Scrb), and ad-PGC-1␣ RNA interference [RNAi] ) and plasmids encoding PGC-1␣ and GR were kindly provided by Dr Jiandie Lin (Life Sciences Institute, University of Michigan, Ann Arbor, MI). PLZF adenoviruses (ad-PLZF) were designed, validated, and synthesized by Yingrun Biotechnologies Inc. All of the adenoviruses were concentrated and purified before use. For in vivo PLZF knockdown, 3 sets of stealth siRNAs for each gene were designed, validated, and synthesized by Invitrogen. To improve gene silencing efficiency, an siRNA cocktail comprising these 3 sets of siRNA oligonucleotides (an equal molar mixture) was used. The sequences of these siRNA oligonucleotides are listed in Supplemental Table 1 . Mouse plzf promoter-luciferase (mplzf-luc) reporter plasmids (Ϫ1121 to Ϫ630) were amplified from mouse genomic DNA using the primers listed in Supplemental Table 2 , and the conserved half GR binding sequence AGAACA was mutated to ACAGCA. These sequences were validated by sequencing and cloned into a pGL3-basic vector. Commercial siRNA oligonucleotides against GR were purchased from Santa Cruz Biotechnology.
In vivo adenovirus transduction
We transduced adenoviruses encoding PLZF or PGC-1␣ as well as their negative control GFP into mice at a dose of 1.0 ϫ 10 9 plaque-forming units per mouse through tail vein injection. Four days after the injection, all mice were killed, and the livers were collected.
Glucose tolerance tests (GTTs), insulin tolerance tests (ITTs), and pyruvate tolerance tests (PTTs)
For GTTs, mice were fasted overnight and intraperitoneally injected with glucose (2 g/kg per normal mouse, 1 g/kg per db/db mouse). For ITTs, mice were fasted for 6 hours and intraperitoneally injected with insulin (0.75 U/kg per normal mouse, 2.5 U/kg per db/db mouse). For PTTs, mice were fasted overnight and then intraperitoneally injected with pyruvate (2 g/kg per normal mouse, 1 g/kg per db/db mouse). Blood glucose levels were measured at 0, 20, 40, 60, and 90 minutes after injection using a glucose monitor (Roche).
Serological analysis
Blood was obtained from the vena cava, and the serum was isolated and stored at Ϫ80°C until analysis. Serum insulin, alanine aminotransferase (ALT), and aspartate aminotransferase 
Cell culture
Mouse AML-12 hepatocytes were cultured with DMEM/ F-12 medium (Gibco) supplemented with insulin, transferrin, selenium (Gibco), and 40 ng/mL dexamethasone (Dex) (SigmaAldrich) in a humidified atmosphere containing 5% CO 2 at 37°C. To demonstrate the effects of gluconeogenic hormones on PLZF expression, AML-12 mouse hepatocytes were treated with 1 M Dex, 1 M hydrocortisone (HCS), 10 M forskolin (FSK), or 1 mM 8-bromo (Br)-cAMP, respectively, for 6 hours. For mplzf-luc activity, 200 ng of reporter plasmids were transfected into AML-12 cells. At 36 hours later, cells were treated with 1 M Dex or 1 M HCS for another 6 hours. Mouse primary hepatocytes were prepared from C57BL/6 mice via the collagenase IV (Gibco) perfusion method and subjected to treatments similar to those performed in AML-12 cells.
Glucose output assays
Mouse primary hepatocytes were isolated and seeded into 6-well plates (1ϫ10 6 cells/well). For the glucose output assay, cells were washed twice with PBS and incubated with glucosefree DMEM medium (pH 7.4, phenol red free, supplemented with 20 mM sodium lactate and 2 mM pyruvate). Six hours later, the medium was assayed for glucose production with a colorimetric kit (Sigma-Aldrich). Values were normalized to the protein content of the whole-cell lysates. Dex (1 M, treatment time: 6 hours) was used as a positive control.
Transient transfection and luciferase reporter assays
Transient transfections were conducted using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. For luciferase reporter assays, 200 ng of reporter plasmids were mixed with 200 ng of GR expression construct in the presence or absence of 500 ng of PGC-1␣ expression construct. Equal amounts of DNA were used for all transfection combinations by addition of appropriate vector DNA. Relative luciferase activities were determined 48 hours after transfection using the DualLuciferase System (Promega). To identify the essential roles of PGC-1␣ and GR in regulating PLZF expression, cells were transfected with Scrb or GR siRNA oligonucleotides together with plasmid vector DNA or plasmids encoding PGC-1␣ for 48 hours. To verify that PLZF functions downstream in PGC-1␣-controlled gluconeogenesis, cells were transfected with Scrb or PLZF siRNA oligonucleotides together with plasmid vector DNA or plasmids encoding PGC-1␣ for 48 hours. All transfection experiments were performed in triplicate.
RT-quantitative PCR (qPCR)
Total RNA was isolated using TRIzol reagents (Invitrogen), reverse transcribed, and analyzed by qPCR using SYBR Green and the Mastercycler ep realplex2 system (Eppendorf, Hamburg, Germany). Primers for mouse 36B4 were included for normalization. A complete list of PCR primers is shown in Supplemental Table 3 .
Western blots
For protein analysis, tissue samples were homogenized, and cells were lysed in radioimmunoprecipitation assay buffer. The protein concentration was quantified with a Dc protein assay reagent (Bio-Rad). Equal amounts of protein were loaded and separated by 10% SDS-PAGE and then transferred onto a polyvinylidene difluoride membrane (Millipore). The membranes were incubated overnight with the appropriate primary antibodies. Bound antibodies were then visualized using horseradish peroxidase-conjugated secondary antibodies. Quantitative analysis was performed by NIH ImageJ 1.32j software. For antibody information, anti-G6Pc, anti-Pck1, anti-GR antibodies were purchased from Santa Cruz Biotechnology, and anti-PGC-1␣ antibody was obtained from Calbiochem. Anti-glyceraldehyde-3-phosphate dehydrogenase, anti-phospho-insulin receptor substrate (IRS) 1 (Ser 307), anti-total IRS1, anti-phospho-Akt (Ser 473), anti-total Akt, anti-phospho-FoxO1 (Ser 319), and anti-total FoxO1 antibodies were purchased from Cell Signaling Technology. Anti-PLZF antibody was from Abcam.
Chromatin immunoprecipitation (ChIP) assay
Chromatin lysates were prepared from AML-12 cells, precleared with protein-A/G agarose beads (Roche), and immunoprecipitated with antibodies against PGC-1␣, trimethylation of lysine 4 of histone 3 (H3K4me3) (Abcam), and acetylated histone 3 (Millipore), or normal mouse IgG (Santa Cruz Biotechnology) in the presence of BSA and salmon sperm DNA. Beads were extensively washed before reverse cross-linking. DNA was purified using a PCR purification kit (Qiagen) and subsequently analyzed by PCR using primers flanking the proximal binding sites for GR on the mouse plzf promoter, as detailed in Supplemental Table 3 .
Coimmunoprecipitation (CoIP) assay
AML-12 cells were lysed in radioimmunoprecipitation assay buffer. After centrifugation, 50 g of protein lysate was incubated with 20 l of protein-A/G agarose beads and 2 g of normal mouse IgG or anti-PGC-1␣. After 24 hours of incubation, the immune complexes were centrifuged and washed 4 times with ice-cold lysis buffer. The immunoprecipitated protein was further analyzed using Western blotting.
Statistical analysis
The groups of data are presented as the means Ϯ SD. The data were analyzed using a one-way ANOVA followed by the Fisher least significant difference post hoc test. The calculations were performed using the SPSS for Windows version 12.5S statistical package (SPSS). A value of P Ͻ .05 was considered statistically significant.
Results
Gluconeogenic signals induce hepatic PLZF expression
To explore whether nutritional signals regulate PLZF expression, we examined the hepatic PLZF expression levels in mice by performing a time course of fasting. As expected, induction of 2 gluconeogenic genes (G6Pc and Pck1) was first detected at 2 hours, persisting during the entire starvation period ( Figure 1A, top panel) . An increase in pgc-1␣ mRNA was also observed after 2 hours and peaked at 5 hours after food deprivation. Interestingly, the hepatic expression levels of plzf mRNA were significantly induced by short-term fasting (2 and 5 hours) and decreased upon refeeding. The protein expression levels of PLZF in the livers showed a similar pattern ( Figure 1A, bottom panel) . Thus, the induction of PLZF in liver is a relatively early event, consistent with a possible role in control of gluconeogenic genes. We also examined PLZF expression levels in other metabolic tissues under the fasting state and found that both PLZF mRNA and protein expression levels were induced in brown adipose tissues and skeletal muscles in response to fasting. However, PLZF was inhibited in white adipose tissues (Supplemental Figure 1) .
The dominant regulator of gluconeogenesis in vivo is insulin. We first examined the expression levels of PLZF in the livers of mice treated with STZ, which is the most commonly used experimental model of insulin-deficient type 1 diabetes. As shown in Figure 1B , both the mRNA and protein expression levels of PLZF were consistently increased in the livers of these mice. In addition, diabetic mice induced by leptin receptor deficiency (db/db) or HFD feeding plus STZ injection develop insulin resistance and show overactivated gluconeogenesis. We found that PLZF expression levels were also increased in the livers of these mice ( Figure 1, C and D) .
Glucocorticoids have long been known to stimulate hepatic gluconeogenesis by binding to GR and inducing transcription of G6Pc and Pck1 genes. On the other hand, cAMP rises in the liver during a fast. Therefore, we investigated whether PLZF is induced by glucocorticoid hormone signals in AML-12 liver cells and mouse primary hepatocytes. Cells were treated with glucocorticoids (Dex and HCS), FSK, an activator of adenylate cyclase that is used to increase intracellular cAMP levels, or 8-Br-cAMP (a cAMP analog). Whereas either FSK or 8-Br-cAMP produced little effect on plzf mRNA, treatment with Dex or HCS caused a large increase in the plzf transcription ( Figure 1E ) in AML-12 cells, which may be due to the enhanced transcriptional activity of the plzf promoter ( Figure 1F ). The induction of plzf mRNA expression levels by Dex showed a dose-and time-dependent manner ( Figure  1G ). Similarly, PLZF protein expression was up-regulated by Dex ( Figure 1H ). In mouse primary hepatocytes, Dex and HCS also promoted PLZF mRNA and protein expression levels, whereas FSK and 8-Br cAMP only increased PLZF expression at the translational level ( Figure 1, I and J) . Specifically, the maximum induction of Dex occurred at 6 hours and then gradually declined ( Figure 1K ).
PLZF activates hepatic gluconeogenesis
To address the possibility that PLZF may regulate aspects of hepatic glucose metabolism, PLZF was overexpressed in cultured liver cells with an adenovirus-based vector. As shown in Figure 2A , forced expression of exogenous PLZF in AML-12 cells by adenovirus infection induced the mRNA and protein expression levels of gluconeogenic genes in a dose-dependent manner. Overexpression of PLZF in mouse primary hepatocytes had similar effects ( Figure 2B ) and functionally increased the glucose production ( Figure 2C) .
In vivo studies indicated that the hepatic expression levels of gluconeogenic genes in normal mice were increased in response to PLZF overexpression, and such inductions came more robustly under the fasting condition ( Figure 2D ). Coincident with these findings, the basal and fasted blood glucose levels were higher ( Figure 2E ). Insulin is an important hormone in regulation of blood glucose homeostasis; thus, we next quantified the serum insulin levels and found they were higher under the fed condition when PLZF was overexpressed in liver ( Figure 2F ). The hyperinsulinemia in these mice might be due to a compensatory response to the elevated # , P Ͻ .05 and ## , P Ͻ .01 group vs ad-GFP/Fasted group. n ϭ 5. E, Basal blood glucose levels under fed or overnight fasted condition. F, Serum insulin levels under fed condition. G-I, GTTs, PTTs, and ITTs. For E-I, *, P Ͻ .05 and **, P Ͻ .01 vs ad-GFP. n ϭ 5. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. doi: 10.1210/me.2014-1164 mend.endojournals.orgblood glucose levels. In addition, these mice also showed impaired glucose and pyruvate tolerance and insulin sensitivity ( Figure 2 , G-I). Collectively, our results strongly suggest that PLZF activates hepatic gluconeogenesis and impairs insulin sensitivity.
Knockdown of PLZF suppresses hepatic gluconeogenesis
We next used a loss-of-function strategy to confirm the above findings. The liver-specific knockdown of PLZF in normal mice did not affect body weight, but significantly decreased blood glucose levels (Supplemental Figure 2A) . Accordingly, the mRNA and protein expression levels of gluconeogenic genes were decreased under both feeding and fasting conditions (Supplemental Figure 2B) . Knockdown of PLZF also caused improved glucose and pyruvate tolerance and insulin sensitivity (Supplemental Figure 2 , C-E). Coincident with the in vivo results, transfection of plasmids encoding PLZF siRNA oligonucleotides in AML-12 cells down-regulated the basal expression levels of gluconeogenic genes and antagonized their induction by Dex (Supplemental Figure 2F ). Finally, PLZF knockdown functionally decreased the glucose production rate in mouse primary hepatocytes (Supplemental Figure 2G) .
Knockdown of PLZF ameliorates hyperglycemia in db/db mice
The importance of PLZF in the regulation of hepatic gluconeogenesis under normal physiological conditions has now been shown. However, whether it affects glucose metabolism in pathological settings remains unknown. Therefore, we transduced diabetic db/db mice with scramble or PLZF siRNA oligonucleotides for 3 days and examined the effects of PLZF knockdown on the gluconeogenic pathway and glucose intolerance. Gene expression analysis revealed that RNAi knockdown of PLZF resulted in an approximately 54% reduction in plzf mRNA levels in the liver ( Figure 3A) . The expression of G6Pc and Pck1 was decreased in response to PLZF knockdown ( Figure 3A) .
Compared with those in controls, blood glucose levels were significantly lower in mice with liver-specific PLZF knockdown when measured under fed and fasted conditions ( Figure 3B ). Serum insulin levels were also decreased ( Figure 3C ). Physiologically, these mice showed reduced food intake, water drinking, and body weight ( Figure  3D ). Serological analysis indicated that serum levels of ALT and AST did not alter in these mice ( Figure 3E) , suggesting that the reduction in food intake is not due to the possible liver toxicity caused by PLZF knockdown. More importantly, GTTs, ITTs, and PTTs in these mice revealed that they had improved glucose and pyruvate tolerance and insulin sensitivity (Figure 3, F-H ). These results demonstrate that depletion of PLZF in the liver improves glucose homeostasis in an insulin-resistant state.
PLZF negatively regulates the insulin signaling pathway
The insulin signaling pathway plays a critical role in the regulation of gluconeogenesis. It was interesting to investigate whether PLZF regulates key components in this signaling cascade. As shown in Figure 4A , overexpression of PLZF reduced the phosphorylation levels of IRS1, Akt, and FoxO1 in normal mouse liver under the fed state. Similarly, infection of adenoviruses encoding PLZF in AML-12 cells antagonized insulin-induced phosphorylation of these factors ( Figure 4B ). Conversely, the liver-specific knockdown of PLZF in db/db mice resulted in a marked increase in the phosphorylation of IRS1, Akt, and FoxO1 ( Figure 4C ). In addition, synergistic effects of PLZF siRNA and insulin on the phosphorylation of these factors were observed in vitro ( Figure 4D ). These results suggest that PLZF negatively regulates key components involved in the insulin signaling pathway, which may contribute to the positive control of PLZF in gluconeogenesis.
On the other hand, PLZF has forkhead response elements (A/G TAAA T/C A) on its promoter and is activated by Foxo3a, a FoxO family member (19) . Given the importance of FoxO1 in gluconeogenesis, we questioned whether PLZF expression is conversely controlled by FoxO1. As shown in Supplemental Figure 3 , forced overexpression of FoxO1 by plasmid transfection in AML-12 cells did not alter PLZF mRNA and protein expression levels, thus excluding such a possibility.
PGC-1␣ and GR synergistically activate PLZF expression
PGC-1␣ is a key nuclear coactivator of gluconeogenesis and may serve as an upstream regulator for PLZF expression. Indeed, overexpression of PGC-1␣ increased the mRNA and protein expression levels of PLZF both in vivo ( Figure 5A ) and in vitro (Supplemental Figure 4A) . In contrast, PGC-1␣ knockdown inhibited PLZF expression in the liver ( Figure 5B ) and in cultured AML-12 cells (Supplemental Figure 4B) . ChIP analysis indicated that PGC-1␣ was present near a glucocorticoid responsive element on the proximal plzf promoter ( Figure 5C ). Epigenetically, histone hyperacetylation is associated with transcriptional activation. Similarly, H3K4me3 is also found in activated genes. We found that PGC-1␣ overexpression led to a robust increase in acetylated histone 3 and H3K4me3 levels on the plzf promoter. The knockdown of PGC-1␣ caused opposite results ( Figure 5D ).
These results indicate that PGC-1␣ stimulates plzf transcription by altering the local chromatin environment from a repressive to an active state.
We next attempted to identify the transcriptional factors that mediate the activation of plzf transcription by PGC-1␣. A bioinformatics analysis indicated that the plzf promoter (Ϫ1121 to Ϫ630) possesses a conserved half GR binding sequence AGAACA (20) . Importantly, when this GR binding domain was mutated, Dex-induced activation of plzf-luc was blocked (Supplemental Figure 5A) . Consistent with this finding, induction of PLZF expression by Dex was attenuated in AML-12 cells with GR knockdown (Supplemental Figure 5B ). Furthermore, a reporter gene assay indicated that PGC-1␣ augmented the transcriptional activity of GR on a plzf promoter reporter ( Figure 5E ). However, when the GR binding site was mutated, such synergistic effects disappeared. To confirm that PGC-1␣ requires GR to activate PLZF, we knocked down GR in AML-12 cells and found that PGC-1␣-induced PLZF expression was repressed by the siRNA against GR ( Figure 5F ). Collectively, these results suggest that PGC-1␣ and GR synergistically activate PLZF expression.
PLZF is a downstream effector for PGC-1␣-controlled gluconeogenesis
To explore whether PLZF is a downstream effector for PGC-1␣-controlled gluconeogenesis, we knocked down PLZF in AML-12 cells overexpressing PGC-1␣ and observed that PLZF knockdown inhibited PGC-1␣-induced gluconeogenic gene expression ( Figure 6A ). Moreover, glucose output from mouse primary hepatocytes was decreased by PLZF knockdown (Figure 6B ). At the molecular level, PGC-1␣ reduced Akt phosphorylation in response to insulin treatment, and knockdown of PLZF antagonized the effects of PGC-1␣ ( Figure 6C ). Physically, CoIP analysis demonstrated that PGC-1␣ and PLZF formed a complex in vitro ( Figure 6D ). These data demonstrate that PLZF is an important factor acting downstream of PGC-1␣ in the regulation of the hepatic gluconeogenic program. Liver-specific knockdown of PLZF relieves hyperglycemia in db/db mice. A, Hepatic PLZF and gluconeogenic gene expression. **, P Ͻ .01 vs Scrb. n ϭ 6. B, Basal blood glucose levels. *, P Ͻ .05 vs Scrb/Fed group; **, P Ͻ .01 vs Scrb/Fasted group. n ϭ 6. C, Serum insulin levels under the fed condition. **, P Ͻ .01 vs Scrb group. n ϭ 6. D, Food intake, water drinking, and body weight. *, P Ͻ .05 vs Scrb. n ϭ 6. E, Serum levels of ALT and AST. n.s., no significant difference. n ϭ 6. F-H, GTTs, PTTs, and ITTs. *, P Ͻ .05 and **P Ͻ .01 vs PLZF siRNA (siPLZF). n ϭ 6. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. doi: 10.1210/me.2014-1164 mend.endojournals.org
Discussion
PLZF was first identified as a zinc finger family member that exhibited a pronounced effect on promyelocytic leukemia pathology. Recent studies have revealed the versatile biological functions of PLZF by using PLZF-deficient mice as a tool. These mice display major musculoskeletal limb defects with homeotic transformation of vertebral segments, physically disabled cartilage and skeleton patterning, and alterations in digit formation (21) . PLZF Ϫ/Ϫ male mice also show partial sterility caused by markedly impaired spermatogenesis (22) . More importantly, PLZF expression is lost in many cancer cells (23), which is believed to transform cells to malignancy (24) . Indeed, we found that PLZF expression was lower in human hepatoma HepG 2 cells than that in the normal liver cell line LO2 (Qian, J., Zhang, W., Wang, D., unpublished data). Therefore, although the exact mechanism has yet to be elucidated, PLZF is considered to be a tumor suppressor protein (25, 26) . At the molecular level, PLZF functions as a versatile transcriptional regulator, either repressing or activating certain physiological programs by selectively interacting with various chaperones. For example, it recruits nuclear corepressors to form repressive complexes via the N-terminal BTB/POZ domain and then silences the activation of target gene promoters (27) . Conversely, when acting as an activator, PLZF interacts with GATA1 and stimulates megakaryocyte differentiation (28) . In R3T3 cells, PLZF is required for PI3K-P85␣ gene activation, which is a crucial process in cardiac hypertrophy (29) . Thus, the roles of PLZF are variable and are dependent on specific pathophysiological circumstances. Furthermore, the active effects of PLZF on some cellular processes can also be achieved by inhibiting the expression of microRNAs, such as microRNA146a and microRNA-221/222. In these cases, although PLZF essentially functions as a repressor, the overall regulation by PLZF leads to the activation of megakaryopoiesis (30) and melanogenesis (31), respectively.
On the other hand, the metabolic properties of cancer cells diverge significantly from those of normal cells. The best studied metabolic phenotype of cancer is aerobic glycolysis, known as the Warburg effect, which is characterized by increased metabolism of glucose to lactate in the presence of sufficient oxygen (32) . A recent metabolomic analysis indicated that the serum metabolite composition from acute myeloid leukemia patients differs a lot from that of the controls, highlighted by system differences in multiple metabolic pathways including gluconeogenesis (33) . In the liver, gluconeogenesis is a fundamental feature of hepatocytes but is not present in mouse or human malignant hepatocytes (34) . This is particularly interesting when the positive relationship between PLZF and gluconeogenesis is considered. First, both PLZF expression and gluconeogenesis are impaired during the development of liver cancer. Second, Dex is reported to restore gluconeogenesis in malignant liver cells, leading to therapeutic efficacy against hepatocarcinoma (34) . In our system, Dex increases PLZF expression in AML-12 cells. Therefore, PLZF may serve as a node integrating metabolism switch and tumorigenesis.
In addition to its role in glucose homeostasis, PLZF also affects lipid metabolism. A comparative analysis of genome-wide chromatin state maps discovered that PLZF possesses antiadipogenic activity (35) . In the heart, PLZF is robustly induced by dietary fatty acids in a PPAR␣-independent manner (36) . Considering that fatty acids are important energy donors for the healthy heart, PLZF may link dietary lipids to heart function. In our study, hepatic PLZF expression is induced in db/db and diet-induced obese mice, which exhibited severe hepatic steatosis. PLZF is also induced by fasting, which leads to physiological hepatic steatosis. These findings suggest that PLZF may be involved in the pathogenesis of lipid dysregulation and accumulation. Further studies are required to elucidate the role of PLZF in the regulation of lipid metabo- PLZF is required in the IFN-mediated antiviral innate immune response in vivo. On the other hand, the immune response is an energy-demanding biological process accompanied by the consequential reduction in food intake (37); therefore, the host's metabolic activities should be coordinately regulated to increase energy availability. Hepatic gluconeogenesis, as well as muscle catabolism, usually occurs during this process. The requirement for PLZF in both the immune response and gluconeogenesis makes it a very promising molecule finely orchestrating these 2 processes. Activation of PLZF not only drives the transcription of interferon-stimulated genes but also triggers gluconeogenesis to provide sufficient energy for the immune defense. PLZF robustly responds to glucocorticoids, which are synthesized and secreted by the adrenal cortex. Through binding to GR, glucocorticoids regulate many essential biological functions, such as lipolysis (38) , gluconeogenesis (39) , and cardiovascular (40) and immunological processes (41) . The induction of PLZF by glucocorticoids has been shown in various cells, including the T47D/A1-2 breast cancer cell line (42) , primary human endometrial stromal cells, and myometrial smooth muscle cells (43) . Importantly, such induction is believed to be, in part, the cause of breast cancer cell death after Dex treatment (42) . In agreement with previous studies, we also found that PLZF is induced by Dex and HCS in liver cells. In contrast, PLZF expression is not altered in the glucocorticoid-treated KG-1 cell line (human Caucasian bone marrow myelogenous leukemia), although these cells have endogenous GR (43) . This finding indicates that induction of PLZF by glucocorticoids is a cell type-specific event caused by the interaction of GR with cell-specific cofactors.
Hepatic insulin signaling ranks as the most important pathway in regulation of glucose homeostasis. When insulin is secreted, it will bind to the insulin receptors located in the cell membrane, which in turn phosphorylate and activate IRS1 and IRS2. Both substrates in active forms trigger the PI3K/Akt cascade to inhibit FoxO1 transcriptional activity, thus turning off the gluconeogenesis by repressing key regulators, such as PGC-1␣ and gluconeogenic genes (44) . In this view, the IRS/Akt/FoxO1 signaling axis contributes importantly to insulin actions. In our study, we found that PLZF negatively regulates the insulin signaling pathway by decreasing the phosphorylation of IRS1, Akt, and FoxO1 in normal mice. This may contribute to the impaired insulin sensitivity observed in vivo. Therefore, the elevated blood glucose levels induced by PLZF not only are due to its positive regulation of gluconeogenesis but also are dependent on its negative effects on the insulin signaling pathway. Our results col- lectively demonstrate that PLZF regulates glucose homeostasis in a systemic manner. More interestingly, PLZF is induced in energy-consuming tissues (brown adipose tissues and skeletal muscles) but is inhibited in energystoring tissues (white adipose tissues), under the fasting state. Further studies are required to elucidate how nutritional signals coordinately regulate PLZF expression in various metabolic tissues to achieve the balance of energy metabolism.
Taken together, our results reveal a positive role for PLZF in the regulation of hepatic gluconeogenesis ( Figure  6E ), which expands our knowledge for understanding the important metabolic coordination necessary for proper blood glucose control. Because gluconeogenesis is tightly linked to the pathogenesis of various diseases, such as tumor, infections, and metabolic diseases, manipulation of PLZF expression levels may offer a useful strategy to treat these diseases in the view of metabolic control.
